Opinion

Video

Patient Burden Associated with Pneumococcal Disease

Author(s):

Christina M. Madison, PharmD, FCCP, AAHIVP,Mary Barna Bridgeman, PharmD, BCPS, BCGP, FASCP

A medical professional examines the significant patient burden imposed by pneumococcal infections, highlighting how this burden drove the development of innovative vaccine technologies.

  1. Discuss the patient burden of pneumococcal infections that led to the development of novel vaccines.

Newsletter

Stay informed on drug updates, treatment guidelines, and pharmacy practice trends—subscribe to Pharmacy Times for weekly clinical insights.

Subscribe Now!
Related Videos
2 experts are featured in this series.
2 experts are featured in this series.
2 experts are featured in this series.
2 experts are featured in this series.
2 experts are featured in this series.
2 experts are featured in this series.
Related Content
Woman applying moisturizing lotion cream on hand palm, easing aches. Lady experiencing severe arthritis rheumatics pains, massaging, warming up arm.
July 14th 2025

Pneumococcal Vaccination Linked With Reduced COVID-19 Hospitalization, Death in Inflammatory Rheumatic Diseases

Luke Halpern, Assistant Editor
pharmacy focus oncology edition
May 12th 2025

Insights from a Pharmacy Times Peer Exchange: Emerging ADCs and Real-World Management

Alexandra Gerlach, Associate Editor
Bacterial pneumonia, medical concept. 3D illustration showing rod-shaped bacteria inside alveoli.
July 4th 2025

Hospitalized Adults With Community-Acquired Pneumonia Suffer Significant Morbidity Post Discharge

Luke Halpern, Assistant Editor
Insights from a Pharmacy Times Peer Exchange: ADC Drug Design and HER2 Ultra-Low Breast Cancer Indiciations
April 29th 2025

Insights from a Pharmacy Times Peer Exchange: ADC Drug Design and HER2 Ultra-Low Breast Cancer Indiciations

Alexandra Gerlach, Associate Editor
PNEUMOVAX box, pneumococcal vaccine for treatment of infections caused by bacteria called pneumococcus
June 24th 2025

23-Valent Pneumococcal Polysaccharide Vaccine Provides Protection Up To 6 Years Following Vaccination

Luke Halpern, Assistant Editor
Cropped of black man receiving vaccine shot
June 20th 2025

Expanding Pneumococcal Vaccinations to Healthy Adults Aged 50 to 64 Years Offers Significant Health, Economic Benefits

Luke Halpern, Assistant Editor